J.S NIKHIL RAM

As a skilled medical professional, I am excited to launch my career in the field of Dermatology. With a strong foundation in medical dermatology and a passion for enhancing skin health and aesthetics, I am seeking an opportunity to contribute my expertise to a dynamic team that values innovation and patient well-being

• Provisional Lifetime Membership at Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)
• Life Member of Bangalore Dermatological Society

• Diagnosis & management of dermatological conditions
• RF & EF ablation
• Intralesional therapies
• Platelet-Rich Plasma (PRP) therapy
• Growth Factor Concentrate (GFC) therapy
• LASER & energy-based devices
• Dermatosurgery

• Textbook chapter : Common Skin Problems in Adolescents, IAP-AHA Textbook of Adolescent Medicine
• Original articles published in :

        The Journal of Medical Sciences 

        International Journal of Research in Dermatology

        Clinical Dermatology Review

        Our Dermatology Online Journal

• Case Reports published in :

        Indian Journal of Dermatology

        IADVL Yuvaderma e-bulletin

• A single arm, multi-centric study to evaluate safety, efficacy and Immunogenicity of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis, ICR/22/005
• A Randomized, Multicenter, Double-Blind, 4-Arm, Parallel-Group, Active-Controlled, Phase 3 Study to Compare Efficacy, Safety and Immunogenicity of ADL-018 150 mg and 300 mg with EU-Approved Xolair 150 mg and 300 mg Administered Through Subcutaneous Route Every 4 Weeks in Patients with Chronic Idiopathic Urticaria (CIU) Who Remained Symptomatic Despite Treatment with Approved Doses of H1 Antihistamines, KBS/OMA/01
• A prospective, multi-centre, open-label Phase IV clinical study to evaluate the safety and efficacy of trifarotene (Aklief) 50µg/g cream in subjects with acne vulgaris over 12 weeks, RD.30.SPR.205051
• A Phase 3, Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BP11 Versus EU-Approved Xolair in Patients with Chronic Spontaneous Urticaria Who Are Resistant to H1 Antagonist, BP11-301
• A Randomized, Phase III, Three-Parallel Arm, Assessor-Blind, Active and Placebo Controlled Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of AKP02G2 Cutaneous Spray versus Enstilar Cutaneous Foam in Subjects with Mild to Moderate Psoriasis, C2A03333

Paper and Poster presentation at : 

• BDS - CME 2024
• CUTICON KARNATAKA 2024
• SARCD 2025
• PEDIATRIC DERMATOLOGY UPDATES - 2024
• DERMACON - 2025
• PEDIATRIC DERMATOLOGY UPDATES - 2025.

Award Paper presentation : CUTICON KARNATAKA 2025

• Hindi
• Kannada
• Telugu
• Tamil
• English

• Psoriasis and biologicals
• Urticaria
• Aesthetic dermatology
• Trichology